Polymorphisms in MIR27A Associated with Early-Onset Toxicity in Fluoropyrimidine-Based Chemotherapy.

Publication

Polymorphisms in MIR27A Associated with Early-Onset Toxicity in Fluoropyrimidine-Based Chemotherapy.

Journal Paper/Review - Feb 5, 2015

Amstutz Ursula, Offer Steven M, Sistonen Johanna, Joerger Markus, Diasio Robert B, Largiadèr Carlo R

Citation

Amstutz U, Offer S, Sistonen J, Joerger M, Diasio R, Largiadèr C. Polymorphisms in MIR27A Associated with Early-Onset Toxicity in Fluoropyrimidine-Based Chemotherapy. Clin Cancer Res 2015; 21:2038-44.

Type

Journal Paper/Review (English)

Journal

Clin Cancer Res 2015; 21

Publication Date

Feb 5, 2015

Issn Electronic

1557-3265

Pages

2038-44

Brief description/objective

The microRNA miR-27a was recently shown to directly regulate dihydropyrimidine dehydrogenase (DPD), the key enzyme in fluoropyrimidine catabolism. A common polymorphism (rs895819A>G) in the miR-27a genomic region (MIR27A) was associated with reduced DPD activity in healthy volunteers, but the clinical relevance of this effect is still unknown. Here, we assessed the association of MIR27A germline variants with early-onset fluoropyrimidine toxicity.